(Q35618441)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

review article

1 reference

title

Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference

Christopher S. Kovacs

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

author name string

Pierre Chue

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

language of work or name

1 reference

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

volume

5 Suppl 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

page(s)

62-79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

Barriers to progress--the impact of tolerability problems

17 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Good tolerability equals good results: the patient's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Dropout rates in randomised antipsychotic drug trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

A clinical monitoring form for mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Obesity as a correlate of outcome in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Obesity and the risk of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Postpartum hostility and prolactin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Psychological distress in patients with hyperprolactinaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

The role of prolactin in mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Prolactin levels and adverse events in patients treated with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Orlistat in the treatment of psychopharmacologically induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Prevalence of obesity and weight change during treatment in patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Antipsychotic drug treatment in first-episode mania: a 6-month longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Persistent tardive dyskinesia in bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Tardive dyskinesia and the primary psychiatric diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Prevalence of overweight and obesity in bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Overweight and obesity in the United States: prevalence and trends, 1960-1994

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

The unhealthy lifestyle of people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Depression and risk of heart failure among the elderly: a prospective community-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Risperidone added to clozapine: impact on serum prolactin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Olanzapine increases weight and serum triglyceride levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

Prevalence of sexual dysfunction among newer antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-2406.2003.00063.X

10.1111/J.1399-2406.2003.00063.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14700015%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference